Online inquiry

IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8289MR)

This product GTTS-WQ8289MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8289MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2471MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ4315MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ11524MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ15830MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ15002MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ8479MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2246MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ11MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW